CTLA4 and colorectal carcinoma: In CRC, immune checkpoint blockade targeting PD-1/PD-L1 and CTLA-4 has demonstrated clinical efficacy mainly in tumors with high microsatellite instability and deficient mismatch repair (MSI-H/dMMR) [21,22].